이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

신증후군 연구 네트워크 (NEPTUNE)

2026년 11월 5일 업데이트: Matthias Kretzler, University of Michigan

희귀 질환 임상 연구 네트워크 하의 신증후군 연구 네트워크

Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not surprising that the available therapies are imperfect. The therapies lack a clear biological basis, and as many families have experienced, they are often not beneficial, and in fact may be significantly toxic. Given these observations, it is essential that research be conducted that address these serious obstacles to effectively caring for patients.

In response to a request for applications by the National Institutes of Health, Office of Rare Diseases (NIH, ORD) for the creation of Rare Disease Clinical Research Consortia, a number of affiliated universities joined together with The NephCure Foundation the NIDDK, the ORDR, and the University of Michigan in collaboration towards the establishment of a Nephrotic Syndrome (NS) Rare Diseases Clinical Research Consortium.

Through this consortium the investigators hope to understand the fundamental biology of these rare diseases and aim to bank long-term observational data and corresponding biological specimens for researchers to access and further enrich.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Idiopathic Nephrotic Syndrome (NS) is a rare disease syndrome responsible for approximately 12% of all causes of end-stage kidney disease (ESRD) and up to 20% of ESRD in children. Treatment strategies for Focal and Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD) and Membranous Nephropathy (MN), the major causes of NS, include high dose prolonged steroid therapy, cyclophosphamide, cyclosporine A, tacrolimus, mycophenolate mofetil and other immunosuppressive agents, which all carry significant side effects. Failure to obtain remission using the current treatment approaches frequently results in progression to ESRD with its associated costs, morbidities, and mortality. In the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry, half of the pediatric patients with Steroid Resistant Nephrotic Syndrome required renal replacement therapy within two years of being enrolled in the disease registry. FSGS also has a high recurrence rate following kidney transplantation (30-40%) and is the most common recurrent disease leading to allograft loss.

The prevailing classification of Nephrotic Syndrome categorizes patients into FSGS, MCD, and MN, if in the absence of other underlying causes, glomerular histology shows a specific histological pattern. This classification does not adequately predict the heterogeneous natural history of patients with FSGS, MCD, and MN. Major advances in understanding the pathogenesis of FSGS and MCD have come over the last ten years from the identification of several mutated genes responsible for causing Steroid Resistant Nephrotic Syndrome (SRNS) presenting with FSGS or MCD histopathology in humans and model organisms. These functionally distinct genetic disorders can present with indistinguishable FSGS lesions on histology confirming the presence of heterogeneous pathogenic mechanisms under the current histological diagnoses.

The limited understanding of FSGS, MCD, and MN biology in humans has necessitated a descriptive classification system in which heterogeneous disorders are grouped together. This invariably consigns these heterogeneous patients to the same therapeutic approaches, which use blunt immunosuppressive drugs that lack a clear biological basis, are often not beneficial, and are complicated by significant toxicity. The foregoing shortcomings make a strong case that concerted and innovative investigational strategies combining basic science, translational, and clinical methods should be employed to study FSGS, MCD, and MN. It is for these reasons that the Nephrotic Syndrome Study Network is established to conduct clinical and translational research in patients with FSGS/MCD and MN.

연구 유형

관찰

등록 (추정된)

1200

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • California
      • Los Angeles, California, 미국, 90227
        • 모병
        • University of Southern California-Children's Hospital
        • 수석 연구원:
          • Kevin Lemley, MD, PhD
        • 연락하다:
      • Palo Alto, California, 미국, 94304
        • 모병
        • Stanford University School of Medicine
        • 연락하다:
        • 수석 연구원:
          • Richard Lafayette, MD
      • San Francisco, California, 미국, 94158
        • 아직 모집하지 않음
        • University of California San Francisco Benioff Children's Hospitals
        • 수석 연구원:
          • Paul Brakeman, MD, PhD
        • 연락하다:
      • Torrance, California, 미국, 90502
        • 모병
        • Lundquist Biomedical Research Institute at Harbor UCLA Medical Center
        • 연락하다:
        • 수석 연구원:
          • Sharon Adler, MD
    • Colorado
      • Aurora, Colorado, 미국, 80045
      • Aurora, Colorado, 미국, 80045
        • 아직 모집하지 않음
        • University of Colorado Anschutz School of Medicine
        • 수석 연구원:
          • Amber Podoll, MD
        • 연락하다:
    • Florida
      • Miami, Florida, 미국, 33136
        • 모병
        • University of Miami Miller School of Medicine
        • 연락하다:
        • 수석 연구원:
          • Alessia Fornoni, MD. PhD
    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • 모병
        • Emory University and Children's Healthcare of Atlanta
        • 수석 연구원:
          • Laurence Greenbaum, MD, PhD
        • 연락하다:
    • Illinois
      • Chicago, Illinois, 미국, 60680
        • 모병
        • John Stroger Cook County Hospital
        • 연락하다:
        • 수석 연구원:
          • Ambarish Athavale, MD
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • 모병
        • University of Kansas Medical Center
        • 연락하다:
        • 수석 연구원:
          • Ellen McCarthy, MD
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • 모병
        • Johns Hopkins Medical Institute
        • 연락하다:
        • 수석 연구원:
          • Alicia Neu, MD
        • 부수사관:
          • Michael Choi, MD
      • Bethesda, Maryland, 미국, 20892
        • 완전한
        • Kidney Disease Section, NIDDK, NIH
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • 모병
        • University of Michigan Medical Center
        • 연락하다:
        • 수석 연구원:
          • Matthias Kretzler, MD
        • 연락하다:
          • Amanda Williams, BS - adult
          • 전화번호: 734-615-5017
          • 이메일: amwi@umich.edu
      • Ann Arbor, Michigan, 미국, 48109
        • 모병
        • CS Mott Children's Hospital, University of Michigan
        • 부수사관:
          • Debbie Gipson, MD, MS
        • 연락하다:
    • Minnesota
      • Rochester, Minnesota, 미국, 55905
        • 완전한
        • Mayo Clinic
    • Missouri
      • Kansas City, Missouri, 미국, 64108
        • 모병
        • Children's Mercy Hospital
        • 수석 연구원:
          • Tarak Srivastava, MD
        • 연락하다:
      • St Louis, Missouri, 미국, 63110
        • 아직 모집하지 않음
        • Washington University - St Louis
        • 연락하다:
        • 수석 연구원:
          • Vikas Dharnidharka, MD, PhD
    • New York
      • New Hyde Park, New York, 미국, 11040
        • 모병
        • Cohen Children's Hospital
        • 수석 연구원:
          • Christine Sethna, MD
        • 연락하다:
      • New York, New York, 미국, 10032
        • 모병
        • Columbia University Medical Center
        • 수석 연구원:
          • Andrew Bomback, MD, MPH
        • 연락하다:
      • New York, New York, 미국, 10010
        • 모병
        • New York University Medical Center
        • 연락하다:
        • 수석 연구원:
          • Olga Zhadnova, MD
        • 수석 연구원:
          • Howard Trachtman, MD
        • 연락하다:
      • New York, New York, 미국, 10016
        • 모병
        • Bellevue Hospital
        • 연락하다:
        • 수석 연구원:
          • Laura Barisoni, MD
        • 부수사관:
          • Olga Zhadnova, MD
      • New York, New York, 미국, 10016
        • 모병
        • New York University Veterans Administration
        • 연락하다:
        • 수석 연구원:
          • Laura Barisoni, MD
        • 부수사관:
          • Olga Zhadnova, MD
      • The Bronx, New York, 미국, 11040
        • 모병
        • Montefiore Medical Center
        • 연락하다:
        • 부수사관:
          • Robert Woroniecki, MD
        • 수석 연구원:
          • Frederick Kaskel, MD
    • North Carolina
      • Chapel Hill, North Carolina, 미국, 27599
        • 모병
        • University of North Carolina at Chapel Hill
        • 연락하다:
        • 수석 연구원:
          • Patrick H. Nachman, MD
        • 부수사관:
          • Susan L. Hogan, PhD, MPH
        • 부수사관:
          • Keisha Gibson, MD
        • 연락하다:
      • Charlotte, North Carolina, 미국, 28203
        • 모병
        • Atrium Health Levine Children's Hospital
        • 수석 연구원:
          • Susan Massengill, MD
        • 연락하다:
      • Winston-Salem, North Carolina, 미국, 27157
        • 빼는
        • Wake Forest School of Medicine
    • Ohio
      • Cleveland, Ohio, 미국, 44195
        • 모병
        • Cleveland Clinic
        • 부수사관:
          • Katherine Dell, MD
        • 연락하다:
        • 연락하다:
          • Villarreal
      • Cleveland, Ohio, 미국, 44106
        • 완전한
        • University Hospital Rainbow Babies & Children's Hospital
      • Cleveland, Ohio, 미국, 44109
        • 완전한
        • MetroHealth Hospital at Case Western Medical Center
      • Columbus, Ohio, 미국, 43210
        • 모병
        • The Ohio State University Wexner Medical Center
        • 연락하다:
        • 수석 연구원:
          • Salem Almaani, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19104
        • 모병
        • University of Pennsylvania
        • 연락하다:
        • 수석 연구원:
          • Lawrence Holzman, MD
        • 연락하다:
      • Philadelphia, Pennsylvania, 미국, 19104
        • 모병
        • Children's Hospital of Philadelphia
        • 부수사관:
          • Kevin Meyers, MD
        • 연락하다:
      • Philadelphia, Pennsylvania, 미국, 19140
        • 모병
        • Temple University
        • 연락하다:
        • 수석 연구원:
          • Crystal Gadegbeku, MD
        • 수석 연구원:
          • Iris Lee, MD
    • South Carolina
      • Charleston, South Carolina, 미국, 29425
        • 모병
        • Medical University of South Carolina
        • 수석 연구원:
          • David Selewski, MD, MS
    • Texas
      • Dallas, Texas, 미국, 75390
      • Houston, Texas, 미국, 77030
        • 모병
        • Texas Children's Hospital - Baylor College of Medicine
        • 연락하다:
        • 수석 연구원:
          • Shweta S. Shah, MD
    • Washington
      • Seattle, Washington, 미국, 98195
      • Seattle, Washington, 미국, 98145
      • Spokane, Washington, 미국, 99204
        • 모병
        • Providence Medical Research Center
        • 연락하다:
        • 부수사관:
          • Katherine Tuttle, MD
        • 연락하다:
    • Ontario
      • Richmond Hill, Ontario, 캐나다, L4C 4Z3
        • 완전한
        • York Central Hospital
      • Scarborough Village, Ontario, 캐나다, M1H 3G4
        • 완전한
        • Scarborough Hospital
      • Toronto, Ontario, 캐나다, M4N 3M5
        • 모병
        • Sunnybrook Hospital
        • 수석 연구원:
          • Michelle Hladunewich, MD
        • 연락하다:
      • Toronto, Ontario, 캐나다, L5M 2N1
        • 모병
        • Credit Valley Hospital
        • 부수사관:
          • Phillip Boll, MD
        • 연락하다:
      • Toronto, Ontario, 캐나다, M5G2C4
        • 모병
        • University Health Network
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Daniel Cattran, MD
        • 부수사관:
          • Heather Reich, MD
        • 부수사관:
          • Michelle Hladunewich, MD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

80년 이하 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Patients with signs and symptoms of kidney disease consistent with FSGS, MCD, MN or proteinuric renal disease or pediatric participants not previously biopsied, who present for patient care at participating clinical centers will be eligible for Cohort A (biopsy cohort) study population targeted for enrollment into the NEPTUNE study.

To establish a cohort of pediatric participants with incident nephrotic syndrome, Cohort B, a non-biopsy cohort has been initiated for Protocol V4.0. This population, <19 years of age, presenting for nephrotic syndrome and less than 30 days of immunosuppression therapy exposure, will also be targeted for enrollment into the cNEPTUNE study.

Potential participants willing to receive their initial care and subsequent follow-up study visits at one of these sites are welcome to participate.

설명

Cohort A (biopsy cohort) Inclusion Criteria:

Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following inclusion criteria:

  • Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening/eligibility visit.
  • Scheduled renal biopsy

Cohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:

  • Age <19 years of age

  • Initial presentation with <30 days immunosuppression therapy

  • Proteinuria/nephrotic

    • UA>2+ and edema OR
    • UA>2+ and serum albumin <3 OR
    • UPC > 2g/g and serum albumin <3

Exclusion Criteria (Cohort A&B):

  • Prior solid organ transplant
  • A clinical diagnosis of glomerulopathy without diagnostic renal biopsy
  • Clinical, serological or histological evidence of systemic lupus erythematosus (SLE) as defined by the ARA criteria. Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Pathology Society categories of lupus nephritis, and frequently overlaps with other classification categories of SLE nephritis (68)
  • Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas), genito-urinary malformations with vesico-urethral reflux or renal dysplasia)
  • Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months
  • Unwillingness or inability to give a comprehensive informed consent
  • Unwillingness to comply with study procedures and visit schedule
  • Institutionalized individuals (e.g., prisoners)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
FSGS/MCD Cohort (Cohort A)

Focal Segmental Glomerulosclerosis/Minimal Change Disease (FSGS/MCD) Cohort

Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for FSGS or MCD.

Eligible participants must be scheduled for a clinically indicated renal biopsy.

Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.

MN Cohort (Cohort A)

Membranous Nephropathy (MN) Cohort

Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for MN.

Eligible participants must be scheduled for a clinically indicated renal biopsy.

Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.

Other glomerulopathies cohort

Participants enrolled in NEPTUNE and determined to not have FSGS/MCD or MN will be followed in a third group.

Eligible participants must be scheduled for a clinically indicated renal biopsy.

Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.

cNEPTUNE (Cohort B)

Participants < 19 years of age, with < 30 days exposure to immunosuppression therapy who are not scheduled for renal biopsy.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Event rate of change in urinary protein excretion and renal function.
기간: 60 months

Defined as remission, partial remission and non-remission

60 months
Rate of change in renal function.
기간: 60 months

Defined as:

  1. 25 mls/min/1.73m2 reduction in follow-up estimated GFR (using the 4-variable MDRD equation for ages ≥18 years and modified Schwartz for ages <18 years) compared to baseline estimated GFR
  2. 50% decline in follow-up estimated GFR compared to baseline measurement
  3. End stage renal disease defined as estimated GFR ≤10cc/min, initiation of maintenance dialysis or preemptive kidney transplantation.
60 months

2차 결과 측정

결과 측정
측정값 설명
기간
Quality of Life:
기간: 60 months

Patient-reported outcome will be assessed using Quality of Life questionnaires at regular intervals as stipulated in the visit calendar using the SF-36, PedsQL and the Patient Reported Outcome Measurement Information System (PROMIS) (in the age-appropriate groups).

60 months
Malignancies
기간: 60 months

Any cancer diagnosis of the skin, hematopoietic system, or solid organ after enrollment in NEPTUNE

60 months
Infections, Serious and Systemic
기간: 60 months

Infections including one of the following:

  1. Documented diagnosis of infection of the skin or subcutaneous tissue (e.g. cellulitis), vascular system, peritoneum, or any vital organ requiring the use of parenteral antibiotics and/or oral antibiotics alone or in combination for a treatment interval of ≥72 hours.
  2. Hospitalization for treatment of infection
60 months
Thromboembolic Events
기간: 60 months

Documented diagnosis of one of the following:

  1. Embolic cerebrovascular accident
  2. Deep venous thrombosis
  3. Renal vein thrombosis or
  4. Pulmonary embolus
60 months
Hospitalization
기간: 60 months

Documented hospital admission, including observation for ≥24 hours.

60 months
Emergency Department/ Observation Unit Visit
기간: 60 months

Documented visit to an emergency department or observation unit that does not lead to hospitalization and is less than 24 hours.

60 months
Acute Kidney Injury
기간: 60 months

Documented diagnosis of acute kidney injury as defined by the AKIN (Mehta et al., Critical Care 2007, 11:R31) and/or renal failure requiring renal replacement therapy <3 months.

60 months
Death
기간: 60 months
  1. Documentation of death that is secondary to infection or sepsis.
  2. Cardiovascular/Cerebrovascular-related Death: Sudden death; Myocardial infarction; Congestive heart failure; Primary intractable serious arrhythmia; Peripheral vascular disease; Ischemic cerebrovascular accident; Hemorrhagic cerebrovascular accident; Thromboembolic event
  3. Documentation of death secondary to cancer
  4. Other Death: Documentation of death that does not fall into the above categories.
60 months
New Onset Diabetes
기간: 60 months

Diagnosis of diabetes as indicated by 1 or more of the following not present at NEPTUNE Enrollment:

  1. Documented diagnosis of diabetes in medical record
  2. Casual (non-fasting) blood glucose > 200 mg/dL c) Fasting blood glucose > 126 mg/dL d) 2 hour glucose > 200 after oral glucose tolerance test e) chronic use (>6 mos) hypoglycemic therapy outside of pregnancy f) Hemogloblin A1C >= 6.5%
60 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Matthias Kretzler, MD, University of Michigan

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2010년 4월 1일

기본 완료 (추정된)

2030년 12월 31일

연구 완료 (추정된)

2030년 12월 31일

연구 등록 날짜

최초 제출

2010년 7월 29일

QC 기준을 충족하는 최초 제출

2010년 9월 23일

처음 게시됨 (추정된)

2010년 9월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 6801
  • 1U54DK083912 (미국 NIH 보조금/계약)
  • 1R01DK141114-01A1 (미국 NIH 보조금/계약)

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .